Improving liver regeneration in alcohol-related liver disease through cardiolipin levels.
Restoration and preservation of hepatic cardiolipin levels promotes liver regeneration in AH
This study is looking at whether boosting a substance called cardiolipin in the liver can help it heal better after damage from alcohol-related liver disease, which could lead to new treatments for people with serious liver problems.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-11001991 on NIH RePORTER |
What this research studies
This research investigates how restoring and preserving cardiolipin levels in the liver can enhance the organ's ability to regenerate after injury caused by alcohol-associated hepatitis (AH). The study focuses on understanding the role of mitochondria, which are crucial for energy production in liver cells, and how cardiolipin affects their function. By using both animal models and human cell cultures, the research aims to determine if cardiolipin supplementation can improve liver cell health and promote regeneration. If successful, this approach could lead to new treatment options for patients suffering from severe liver damage due to alcohol.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcohol-associated hepatitis or severe alcohol-related liver disease.
Not a fit: Patients with liver conditions unrelated to alcohol or those who have already undergone liver transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment strategy to improve liver regeneration in patients with alcohol-associated hepatitis.
How similar studies have performed: While the approach of targeting cardiolipin levels in liver regeneration is innovative, preliminary data suggest that similar strategies have shown promise in preclinical models.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Hardesty, Josiah E — University of Louisville
- Study coordinator: Hardesty, Josiah E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.